Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford, and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2023. Even 15 years ago, companies like Radio Shack, AOL, Yahoo, and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.
As the years go by, some companies lose their luster, and others rise to the top of the markets. We've already seen this in the last few decades, with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega-trend will be that knocks Apple, Google, and Amazon off the top rankings of the S&P 500, but we know that companies don't stay on the S&P 500 forever.
We have identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they show negative earnings growth for the next several years. If you own any of these stocks, consider whether they still belong in your portfolio before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.
Marqeta, Inc operates a cloud-based open application programming interface platform that delivers card issuing and transaction processing services. It offers its solutions in various verticals, including financial services, on-demand services, expense management, and e-commerce enablement, as well as buy now, pay later.
Read More
Trailing Twelve Months EPS: ($0.36)
2024 EPS Estimate: $0.01
2025 EPS Estimate: ($0.20)
- Current Stock Price
- $5.37
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $7.13 (32.7% Upside)
IAC Inc, together with its subsidiaries, operates as a media and internet company worldwide. The company publishes original and engaging digital content in the form of articles, illustrations, and videos and images across entertainment, food, home, beauty, travel, health, family, luxury, and fashion areas; and magazines related to women and lifestyle.
Read More
Trailing Twelve Months EPS: ($1.58)
2024 EPS Estimate: $0.09
2025 EPS Estimate: ($1.19)
- Current Stock Price
- $51.44
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $80.25 (56.0% Upside)
#3 - Global Business Travel Group (NYSE:GBTG)
Global Business Travel Group, Inc provides business-to-business (B2B) travel platform in the United States and internationally. The company's platform offers a suite of technology-enabled solutions to business travelers and clients; travel content suppliers, such as airlines, hotels, ground transportation, and aggregators; and third-party travel agencies.
Read More
Trailing Twelve Months EPS: ($0.39)
2024 EPS Estimate: ($0.11)
2025 EPS Estimate: ($0.15)
- Current Stock Price
- $6.73
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $9.00 (33.7% Upside)
Atlassian Corporation, through its subsidiaries, designs, develops, licenses, and maintains various software products worldwide. Its product portfolio includes Jira Software and Jira Work Management, a project management system that connects technical and business teams so they can better plan, organize, track and manage their work and projects; Confluence, a connected workspace that organizes knowledge across all teams to move work forward; and Trello, a collaboration and organization product that captures and adds structure to fluid and fast-forming work for teams.
Read More
Trailing Twelve Months EPS: ($0.63)
2024 EPS Estimate: ($0.22)
2025 EPS Estimate: ($0.23)
- Current Stock Price
- $177.32
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $228.81 (29.0% Upside)
#5 - Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Read More
Trailing Twelve Months EPS: ($0.16)
2024 EPS Estimate: ($0.26)
2025 EPS Estimate: ($0.32)
- Current Stock Price
- $11.55
- Consensus Rating
- Buy
- Ratings Breakdown
- 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $13.50 (16.9% Upside)
#6 - Frontier Communications Parent (NASDAQ:FYBR)
Frontier Communications Parent, Inc, together with its subsidiaries, provides communication and technology services in the United States. It offers broadband, video, voice, and other value-added services. The company also provides data and Internet, including broadband networking services; data-based voice over internet protocol, unified communications, long-distance, and voice messaging services; video services under the Frontier TV brand; access services; hardware and network solutions; and packages of services.
Read More
Trailing Twelve Months EPS: $0.11
2024 EPS Estimate: ($0.44)
2025 EPS Estimate: ($0.81)
- Current Stock Price
- $28.01
- P/E Ratio
- 254.6
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $30.38 (8.4% Upside)
Zscaler, Inc operates as a cloud security company worldwide. The company offers Zscaler Internet Access solution that provides users, workloads, IoT, and OT devices secure access to externally managed applications, including software-as-a-service (SaaS) applications and internet destinations; and Zscaler Private Access solution, which is designed to provide access to managed applications hosted internally in data centers, and private or public clouds.
Read More
Trailing Twelve Months EPS: ($0.51)
2024 EPS Estimate: ($0.34)
2025 EPS Estimate: ($0.37)
- Current Stock Price
- $181.36
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 27 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $225.21 (24.2% Upside)
GitLab Inc, through its subsidiaries, develops software for the software development lifecycle in the United States, Europe, and the Asia Pacific. It offers GitLab, a DevOps platform, which is a single application that leads to faster cycle time and allows visibility throughout and control over various stages of the DevOps lifecycle.
Read More
Trailing Twelve Months EPS: ($2.75)
2024 EPS Estimate: ($0.50)
2025 EPS Estimate: ($0.55)
- Current Stock Price
- $53.37
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 21 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $67.30 (26.1% Upside)
Liberty Global Ltd., together with its subsidiaries, provides broadband internet, video, fixed-line telephony, and mobile communications services to residential and business customers. It offers value-added broadband services, such as WiFi features, security, anti-virus, firewall, spam protection, smart home services, online storage solutions, and web spaces; and Connect Box that delivers in-home Wi-Fi service.
Read More
Trailing Twelve Months EPS: ($6.47)
2024 EPS Estimate: ($0.61)
2025 EPS Estimate: ($0.71)
- Current Stock Price
- $19.40
- Consensus Rating
- Hold
- Ratings Breakdown
- 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $24.58 (26.7% Upside)
EchoStar Corporation, together with its subsidiaries, provides networking technologies and services worldwide. The company operates in four segments: Pay-TV, Retail Wireless, 5G Network Deployment, Broadband and Satellite Services. The Pay-TV segment offers a direct broadcast and fixed satellite services; designs, develops, and distributes receiver system; and provides digital broadcast operations, including satellite uplinking/downlinking, transmission and, other services to third-party pay-TV providers; and multichannel, live-linear and on-demand streaming over-the-top internet-based domestic, international, Latino, and Freestream video programming services under the DISH and SLING brand names.
Read More
Trailing Twelve Months EPS: ($7.71)
2024 EPS Estimate: ($1.50)
2025 EPS Estimate: ($3.14)
- Current Stock Price
- $20.31
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $23.00 (13.2% Upside)
#11 - MoonLake Immunotherapeutics (NASDAQ:MLTX)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Trailing Twelve Months EPS: ($0.75)
2024 EPS Estimate: ($1.21)
2025 EPS Estimate: ($1.95)
- Current Stock Price
- $44.77
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $79.00 (76.5% Upside)
#12 - Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
Trailing Twelve Months EPS: ($6.32)
2024 EPS Estimate: ($2.15)
2025 EPS Estimate: ($5.94)
- Current Stock Price
- $48.05
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $50.67 (5.4% Upside)
#13 - Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
Trailing Twelve Months EPS: ($0.93)
2024 EPS Estimate: ($1.09)
2025 EPS Estimate: ($1.42)
- Current Stock Price
- $65.98
- Consensus Rating
- Buy
- Ratings Breakdown
- 10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $111.78 (69.4% Upside)
#14 - QuantumScape (NYSE:QS)
QuantumScape Corporation, a research and development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Trailing Twelve Months EPS: ($0.96)
2024 EPS Estimate: ($0.89)
2025 EPS Estimate: ($0.93)
- Current Stock Price
- $7.06
- Consensus Rating
- Reduce
- Ratings Breakdown
- 1 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $6.45 (8.6% Downside)
#15 - Brookfield Renewable (NYSE:BEPC)
Brookfield Renewable Corporation owns and operates a portfolio of renewable power and sustainable solution assets primarily in the United States, Europe, Colombia, and Brazil. It operates hydroelectric, wind, solar, and distributed energy and sustainable solutions with an installed capacity of approximately 19,161 megawatts.
Read More
Trailing Twelve Months EPS: ($0.46)
2024 EPS Estimate: ($0.99)
2025 EPS Estimate: ($1.11)
- Current Stock Price
- $28.46
- Dividend Yield
- 4.98%
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $33.50 (17.7% Upside)
#16 - Roivant Sciences (NASDAQ:ROIV)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Trailing Twelve Months EPS: $5.06
2024 EPS Estimate: ($1.12)
2025 EPS Estimate: ($1.21)
- Current Stock Price
- $10.80
- P/E Ratio
- 2.1
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.10 (58.3% Upside)
Lucid Group, Inc a technology company, designs, engineers, manufactures, and sells electric vehicles (EV), EV powertrains, and battery systems. It also designs and develops proprietary software in-house for Lucid vehicles. The company sells vehicles directly to consumers through its retail sales network and direct online sales, including Lucid Financial Services.
Read More
Trailing Twelve Months EPS: ($1.27)
2024 EPS Estimate: ($1.17)
2025 EPS Estimate: ($1.23)
- Current Stock Price
- $3.38
- Consensus Rating
- Reduce
- Ratings Breakdown
- 0 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings.
- Consensus Price Target
- $4.14 (22.5% Upside)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Read More
Trailing Twelve Months EPS: ($1.03)
2024 EPS Estimate: ($1.70)
2025 EPS Estimate: ($1.88)
- Current Stock Price
- $64.41
- Consensus Rating
- Buy
- Ratings Breakdown
- 14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $78.00 (21.1% Upside)
Roblox Corporation develops and operates an online entertainment platform in the United States and internationally. It offers Roblox Studio, a free toolset that allows developers and creators to build, publish, and operate 3D experiences, and other content; Roblox Client, an application that allows users to explore 3D experience; and Roblox Cloud, which provides services and infrastructure that power the platform.
Read More
Trailing Twelve Months EPS: ($1.86)
2024 EPS Estimate: ($1.66)
2025 EPS Estimate: ($1.67)
- Current Stock Price
- $40.51
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 16 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $42.59 (5.1% Upside)
#20 - IDEAYA Biosciences (NASDAQ:IDYA)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Read More
Trailing Twelve Months EPS: ($2.01)
2024 EPS Estimate: ($2.22)
2025 EPS Estimate: ($2.70)
- Current Stock Price
- $42.39
- Consensus Rating
- Buy
- Ratings Breakdown
- 14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $52.92 (24.8% Upside)
More Investing Slideshows:
